Crossmark

MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression

Crossref DOI link: https://doi.org/10.1186/s12885-018-4056-8

Published Online: 2018-02-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zhikun

Li, Jie

Chen, Jun

Shan, Qiaonan

Dai, Haojiang

Xie, Haiyang

Zhou, Lin

Xu, Xiao

Zheng, Shusen
Funding

Funding for this research was provided by:

National High-Tech R&D Program of China (No.2012AA020204)

Yangtze River scholar project, projects of medical and health technology program in Zhejiang province (2015KYB151 and 2015117734)
More Information

Article History

Received: 26 December 2016

Accepted: 25 January 2018

First Online: 20 February 2018

Ethics approval and consent to participate

: This study was approved by the Ethics Committee of the First Hospital of Zhejiang University in accordance with the Declaration of Helsinki, and all subjects in this study provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.